1-6 of 6
Claire Tsao
Close
Sort by
Journal Articles

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Inhye E. Ahn, MD, Xin Tian, Maher Albitar, MD, Sarah E. M. Herman, PhD, Erika M. Cook, Susan Soto, Wanlong Ma, David Ipe, L. Claire Tsao, Mei Cheng, James P. Dean, Adrian Wiestner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 186.
https://doi.org/10.1182/blood-2018-99-110326
Published: 2018
Journal Articles

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Clinical Trials & Observations
Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K. Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying-Ming Jou, Michael Robbins, Antonio Palumbo
Journal: Blood
Blood (2016) 127 (23): 2833–2840.
https://doi.org/10.1182/blood-2016-01-694604
Published: 2016
Includes: Supplemental data
Journal Articles

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, Sundar Jagannath, MD, Philippe Moreau, MD, Andrzej Jakubowiak, MD PhD, Marc S Raab, MD PhD, Thierry Facon, MD, Ravi Vij, MD, Darrell White, MD, Donna E. Reece, MD, Lotfi Benboubker, MD PhD, Jeffrey Zonder, MD, L. Claire Tsao, PhD, Kenneth C. Anderson, MD, Eric Bleickardt, MD, Anil K Singhal, MD, Sagar Lonial, MD
Journal: Blood
Blood (2014) 124 (21): 302.
https://doi.org/10.1182/blood.V124.21.302.302
Published: 2014
Journal Articles

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Marc S Raab, MD, PhD, Thierry Facon, MD, Ravi Vij, MD, Philippe Moreau, MD, Donna E. Reece, MD, FRCPC, Darrell J. White, MD, Lotfi Benboubker, MD, PhD, Jeffrey A. Zonder, MD, Jean-Francois Rossi, MD, PhD, Claire Tsao, Teresa Parli, Glenn Kroog, MD, Anil K Singhal, Paul G. Richardson, MD
Journal: Blood
Blood (2011) 118 (21): 303.
https://doi.org/10.1182/blood.V118.21.303.303
Published: 2011
Journal Articles

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Paul G. Richardson, MD, Philippe Moreau, MD, Andrzej J Jakubowiak, MD, PhD, Thierry Facon, MD, Sundar Jagannath, MD, Ravi Vij, MD, Donna E Reece, MD, Darrell J White, MD, Marc S Raab, MD, PhD, Lotfi Benboubker, MD, PhD, Jean-Francois Rossi, MD, PhD, Claire Tsao, PhD, John Fry, David Berman, MD, PhD, Anil K Singhal, MD, Sagar Lonial, MD
Journal: Blood
Blood (2010) 116 (21): 986.
https://doi.org/10.1182/blood.V116.21.986.986
Published: 2010
Journal Articles

Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study

Sagar Lonial, MD, Ravi Vij, MD, Jean-Luc Harousseau, MD, Thierry Facon, MD, Philippe Moreau, MD, Xavier Leleu, MD, PhD, Amitabha Mazumder, MD, Jonathan L Kaufman, MD, Christopher E Westland, Claire Tsao, PhD, Anil K Singhal, MD, Sundar Jagannath, MD
Journal: Blood
Blood (2010) 116 (21): 1936.
https://doi.org/10.1182/blood.V116.21.1936.1936
Published: 2010